{
  "success": true,
  "pagesUsed": [
    1,
    2,
    3,
    6,
    7,
    8,
    21,
    22,
    23,
    24
  ],
  "modelUsed": "gemini-3-flash-preview",
  "objectivesEndpoints": {
    "objectives": [
      {
        "id": "obj_1",
        "name": "Primary Efficacy Objective",
        "text": "To evaluate the efficacy of atezolizumab in combination with bevacizumab compared with sorafenib on the basis of the co-primary efficacy endpoints of OS and IRF-assessed PFS according to RECIST v1.1.",
        "level": {
          "code": "C85826",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Trial Primary Objective",
          "instanceType": "Code"
        },
        "endpointIds": [
          "ep_1",
          "ep_2"
        ],
        "instanceType": "Objective"
      },
      {
        "id": "obj_2",
        "name": "Secondary Efficacy Objective",
        "text": "Secondary Efficacy Endpoints",
        "level": {
          "code": "C85827",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Trial Secondary Objective",
          "instanceType": "Code"
        },
        "endpointIds": [
          "ep_3"
        ],
        "instanceType": "Objective"
      },
      {
        "id": "obj_3",
        "name": "Safety Objective",
        "text": "Safety Analyses",
        "level": {
          "code": "C85827",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Trial Secondary Objective",
          "instanceType": "Code"
        },
        "endpointIds": [
          "ep_4"
        ],
        "instanceType": "Objective"
      },
      {
        "id": "obj_4",
        "name": "Exploratory Efficacy Objective",
        "text": "Exploratory Efficacy Endpoints",
        "level": {
          "code": "C163559",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Trial Exploratory Objective",
          "instanceType": "Code"
        },
        "endpointIds": [
          "ep_5"
        ],
        "instanceType": "Objective"
      }
    ],
    "endpoints": [
      {
        "id": "ep_1",
        "name": "Overall Survival",
        "text": "Overall survival is defined as the time from the date of randomization to the date of death from any cause.",
        "level": {
          "code": "C98772",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Primary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Efficacy"
      },
      {
        "id": "ep_2",
        "name": "IRF-Assessed Progression-Free Survival",
        "text": "Independent Review Facility-assessed PFS is defined as the time from randomization to the occurrence of disease progression as determined by the IRF according to RECIST v1.1, or death from any cause, whichever occurs first.",
        "level": {
          "code": "C98772",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Primary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Efficacy"
      },
      {
        "id": "ep_3",
        "name": "Secondary Efficacy Endpoints",
        "text": "Secondary Efficacy Endpoints (as listed in Section 6.4.2)",
        "level": {
          "code": "C98781",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Secondary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Efficacy"
      },
      {
        "id": "ep_4",
        "name": "Safety Endpoints",
        "text": "Safety Analyses (as listed in Section 6.5)",
        "level": {
          "code": "C98781",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Secondary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Safety"
      },
      {
        "id": "ep_5",
        "name": "Exploratory Efficacy Endpoints",
        "text": "Exploratory Efficacy Endpoints (as listed in Section 6.4.3)",
        "level": {
          "code": "C98724",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Exploratory Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Efficacy"
      }
    ],
    "estimands": [
      {
        "id": "est_1",
        "name": "Primary Efficacy Estimand for Overall Survival",
        "populationSummary": "Adult patients with hepatocellular carcinoma meeting eligibility criteria (Global enrollment phase) Summary measure: Hazard ratio (stratified).",
        "analysisPopulationId": "est_1_pop",
        "variableOfInterestId": "ep_1",
        "interventionIds": [
          "est_1_int"
        ],
        "intercurrentEvents": [
          {
            "id": "ice_1",
            "name": "Treatment discontinuation",
            "text": "Discontinuation of study treatment due to toxicity or other reasons",
            "strategy": "Treatment Policy",
            "instanceType": "IntercurrentEvent"
          },
          {
            "id": "ice_2",
            "name": "Subsequent anti-cancer therapy",
            "text": "Initiation of non-protocol anti-cancer therapies after progression",
            "strategy": "Treatment Policy",
            "instanceType": "IntercurrentEvent"
          }
        ],
        "instanceType": "Estimand",
        "treatment": "Atezolizumab 1200 mg IV + Bevacizumab 15 mg/kg IV every 21 days vs Sorafenib 400 mg BID",
        "analysisPopulation": "Adult patients with hepatocellular carcinoma meeting eligibility criteria (Global enrollment phase)",
        "variableOfInterest": "Time from randomization to death from any cause",
        "summaryMeasure": "Hazard ratio (stratified)"
      },
      {
        "id": "est_2",
        "name": "Primary Efficacy Estimand for Progression-Free Survival",
        "populationSummary": "Adult patients with hepatocellular carcinoma meeting eligibility criteria (Global enrollment phase) Summary measure: Hazard ratio (stratified).",
        "analysisPopulationId": "est_2_pop",
        "variableOfInterestId": "ep_2",
        "interventionIds": [
          "est_2_int"
        ],
        "intercurrentEvents": [
          {
            "id": "ice_3",
            "name": "Treatment discontinuation",
            "text": "Discontinuation of study treatment prior to progression",
            "strategy": "Treatment Policy",
            "instanceType": "IntercurrentEvent"
          },
          {
            "id": "ice_4",
            "name": "Missing tumor assessments",
            "text": "Patient has no post-baseline tumor assessments",
            "strategy": "Treatment Policy",
            "instanceType": "IntercurrentEvent"
          }
        ],
        "instanceType": "Estimand",
        "treatment": "Atezolizumab 1200 mg IV + Bevacizumab 15 mg/kg IV every 21 days vs Sorafenib 400 mg BID",
        "analysisPopulation": "Adult patients with hepatocellular carcinoma meeting eligibility criteria (Global enrollment phase)",
        "variableOfInterest": "Time from randomization to IRF-assessed disease progression (RECIST v1.1) or death from any cause",
        "summaryMeasure": "Hazard ratio (stratified)"
      }
    ],
    "summary": {
      "primaryObjectives": 1,
      "secondaryObjectives": 2,
      "exploratoryObjectives": 1,
      "totalEndpoints": 5,
      "totalEstimands": 2
    }
  },
  "rawResponse": {
    "objectives": [
      {
        "id": "obj_1",
        "name": "Primary Efficacy Objective",
        "text": "To evaluate the efficacy of atezolizumab in combination with bevacizumab compared with sorafenib on the basis of the co-primary efficacy endpoints of OS and IRF-assessed PFS according to RECIST v1.1.",
        "level": {
          "code": "C85826",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Trial Primary Objective",
          "instanceType": "Code"
        },
        "endpointIds": [
          "ep_1",
          "ep_2"
        ],
        "instanceType": "Objective"
      },
      {
        "id": "obj_2",
        "name": "Secondary Efficacy Objective",
        "text": "Secondary Efficacy Endpoints",
        "level": {
          "code": "C85827",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Trial Secondary Objective",
          "instanceType": "Code"
        },
        "endpointIds": [
          "ep_3"
        ],
        "instanceType": "Objective"
      },
      {
        "id": "obj_3",
        "name": "Safety Objective",
        "text": "Safety Analyses",
        "level": {
          "code": "C85827",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Trial Secondary Objective",
          "instanceType": "Code"
        },
        "endpointIds": [
          "ep_4"
        ],
        "instanceType": "Objective"
      },
      {
        "id": "obj_4",
        "name": "Exploratory Efficacy Objective",
        "text": "Exploratory Efficacy Endpoints",
        "level": {
          "code": "C163559",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Trial Exploratory Objective",
          "instanceType": "Code"
        },
        "endpointIds": [
          "ep_5"
        ],
        "instanceType": "Objective"
      }
    ],
    "endpoints": [
      {
        "id": "ep_1",
        "name": "Overall Survival",
        "text": "Overall survival is defined as the time from the date of randomization to the date of death from any cause.",
        "level": {
          "code": "C98772",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Primary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Efficacy"
      },
      {
        "id": "ep_2",
        "name": "IRF-Assessed Progression-Free Survival",
        "text": "Independent Review Facility-assessed PFS is defined as the time from randomization to the occurrence of disease progression as determined by the IRF according to RECIST v1.1, or death from any cause, whichever occurs first.",
        "level": {
          "code": "C98772",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Primary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Efficacy"
      },
      {
        "id": "ep_3",
        "name": "Secondary Efficacy Endpoints",
        "text": "Secondary Efficacy Endpoints (as listed in Section 6.4.2)",
        "level": {
          "code": "C98781",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Secondary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Efficacy"
      },
      {
        "id": "ep_4",
        "name": "Safety Endpoints",
        "text": "Safety Analyses (as listed in Section 6.5)",
        "level": {
          "code": "C98781",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Secondary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Safety"
      },
      {
        "id": "ep_5",
        "name": "Exploratory Efficacy Endpoints",
        "text": "Exploratory Efficacy Endpoints (as listed in Section 6.4.3)",
        "level": {
          "code": "C98724",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Exploratory Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Efficacy"
      }
    ],
    "estimands": [
      {
        "id": "est_1",
        "name": "Primary Efficacy Estimand for Overall Survival",
        "populationSummary": "Adult patients with hepatocellular carcinoma meeting eligibility criteria (Global enrollment phase) Summary measure: Hazard ratio (stratified).",
        "analysisPopulationId": "est_1_pop",
        "variableOfInterestId": "ep_1",
        "interventionIds": [
          "est_1_int"
        ],
        "intercurrentEvents": [
          {
            "id": "ice_1",
            "name": "Treatment discontinuation",
            "text": "Discontinuation of study treatment due to toxicity or other reasons",
            "strategy": "Treatment Policy",
            "instanceType": "IntercurrentEvent"
          },
          {
            "id": "ice_2",
            "name": "Subsequent anti-cancer therapy",
            "text": "Initiation of non-protocol anti-cancer therapies after progression",
            "strategy": "Treatment Policy",
            "instanceType": "IntercurrentEvent"
          }
        ],
        "instanceType": "Estimand",
        "treatment": "Atezolizumab 1200 mg IV + Bevacizumab 15 mg/kg IV every 21 days vs Sorafenib 400 mg BID",
        "analysisPopulation": "Adult patients with hepatocellular carcinoma meeting eligibility criteria (Global enrollment phase)",
        "variableOfInterest": "Time from randomization to death from any cause",
        "summaryMeasure": "Hazard ratio (stratified)"
      },
      {
        "id": "est_2",
        "name": "Primary Efficacy Estimand for Progression-Free Survival",
        "populationSummary": "Adult patients with hepatocellular carcinoma meeting eligibility criteria (Global enrollment phase) Summary measure: Hazard ratio (stratified).",
        "analysisPopulationId": "est_2_pop",
        "variableOfInterestId": "ep_2",
        "interventionIds": [
          "est_2_int"
        ],
        "intercurrentEvents": [
          {
            "id": "ice_3",
            "name": "Treatment discontinuation",
            "text": "Discontinuation of study treatment prior to progression",
            "strategy": "Treatment Policy",
            "instanceType": "IntercurrentEvent"
          },
          {
            "id": "ice_4",
            "name": "Missing tumor assessments",
            "text": "Patient has no post-baseline tumor assessments",
            "strategy": "Treatment Policy",
            "instanceType": "IntercurrentEvent"
          }
        ],
        "instanceType": "Estimand",
        "treatment": "Atezolizumab 1200 mg IV + Bevacizumab 15 mg/kg IV every 21 days vs Sorafenib 400 mg BID",
        "analysisPopulation": "Adult patients with hepatocellular carcinoma meeting eligibility criteria (Global enrollment phase)",
        "variableOfInterest": "Time from randomization to IRF-assessed disease progression (RECIST v1.1) or death from any cause",
        "summaryMeasure": "Hazard ratio (stratified)"
      }
    ]
  }
}